Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
27 3월 2023 - 10:00PM
Silo Pharma, Inc. (Nasdaq: SILO) (the “Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it has filed a provisional patent application titled “Methods
and Compositions for Pain Management.”
The methods and compositions described in the
patent application can be used in ameliorating pain, including
chronic pain such as fibromyalgia, which occurs in approximately 2%
of the United States general population. Fibromyalgia is a chronic
condition causing pain to the connective tissues throughout the
body including muscles, ligaments, and tendons. Musculoskeletal
pain is often accompanied by sleep difficulties, fatigue, mood
disorders, and problems with memory and concentration.
Fibromyalgia is the initially targeted
indication for the Company’s drug, SP-26. “This provisional patent
application supports our multi-pronged strategy for advancing SP-26
into the clinic. The Company is working towards submitting an IND
package to the FDA and pursuing the 505(b)(2) regulatory pathway
for SP-26. We believe our drug would serve a critical need in a
largely inadequate treatment landscape for chronic pain including
fibromyalgia,” said Eric Weisblum, Chief Executive Officer of the
Company.
The Company’s intellectual property and
technology rights for the treatment of rare diseases span over six
issued and provisional patents with additional patent applications
pending.
About Silo Pharma
Silo Pharma. Inc. is a development-stage
biopharmaceutical company focused on merging traditional
therapeutics with psychedelic research for people suffering from
indications such as PTSD, Alzheimer’s disease, and other rare
neurological disorders. Silo’s mission is to identify assets to
license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information visit www.silopharma.com
Forward-Looking
Statements
All statements other than statements of
historical fact in this announcement are forward-looking statements
that involve known and unknown risks and uncertainties and are
based on current expectations and projections about future events
and financial trends that the Company believes may affect its
financial condition, results of operations, business strategy, and
financial needs. Investors can identify these forward-looking
statements by words or phrases such as "may," "will," "expect,"
"anticipate," "aim," "estimate," "intend," "plan," "believe,"
"potential," "continue," "is/are likely to" or other similar
expressions. The Company under takes no obligation to update
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024